Antifibrotic therapy in nonalcoholic steatohepatitis: time for a human-centric approach
Antifibrotic therapy in nonalcoholic steatohepatitis: time for a human-centric approach
About this item
Full title
Author / Creator
Publisher
London: Nature Publishing Group UK
Journal title
Language
English
Formats
Publication information
Publisher
London: Nature Publishing Group UK
Subjects
More information
Scope and Contents
Contents
Nonalcoholic steatohepatitis (NASH) might soon become the leading cause of end-stage liver disease and indication for liver transplantation worldwide. Fibrosis severity is the only histological predictor of liver-related morbidity and mortality in NASH identified to date. Moreover, fibrosis regression is associated with improved clinical outcomes....
Alternative Titles
Full title
Antifibrotic therapy in nonalcoholic steatohepatitis: time for a human-centric approach
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10236408
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10236408
Other Identifiers
ISSN
1759-5045
E-ISSN
1759-5053
DOI
10.1038/s41575-023-00796-x
